Another seizure stopped. Another unstoppable day.

Tyler, living with
RNS® System since 2017

*Real person who volunteered to share RNS System experiences

The RNS® System

Help your patients take back their lives. When medications fail, waiting puts patients at risk.

Learn About DRE

Rapid, lasting, unmatched seizure control

The RNS System delivers unmatched seizure control that lets your patients take back their lives1-3. It responds to a patient's unique seizure fingerprint, so they get the treatment they need, when they need it.

Long term median
seizure reduction
of 82% at 3 years1.

See the outcomes

Data Made Simple. Insights Made Clear.

Confident care for patients has never been simpler.

See the benefits
Activity plot showing the early effect of medication in late November

Activity plot showing the early effect of medication in late November.4

Activity plot showing increased electrographic activity at a time when patient reported lack of sleep

Activity plot showing increased electrographic activity at a time when patient reported lack of sleep.

Week by Hour Histogram showing hours when electrographic activity is elevated

Week by Hour Histogram showing hours when electrographic activity is elevated.

How It Works

Stops seizures before they start.

Discover how the RNS System recognizes and responds to your patient's brain patterns.

Learn how it works

Social

Latest NeuroPace Posts

Follow NeuroPace

Easily get your patients started with The RNS® System

Whether you're evaluating your first candidate or you want to establish the RNS System as your standard of care, we are here to help.

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at www.NeuroPace.com/safety. Refer to the labeling for a description of the RNS System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use.

  1. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data.
  2. Morris et al, Neurology, 1999.
  3. Kaufmann et al., Epilepsia, 2024

Note: Therapies were studied using different study designs. Caution must be exercised when comparing results.

  1. Quraishi, et al, Epilepsia, 2020